Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma

References

• Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
   PubMed Web of Science ®Google Scholar
• Ito T, Nguyen MH. Perspectives on the underlying etiology of HCC and its effects on treatment outcomes. J Hepatocell Carcinoma. 2023;10:413–428. doi:10.2147/JHC.S347959
   PubMed Web of Science ®Google Scholar
• Shin HS, Jun BG, Yi SW. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases. Clin Mol Hepatol. 2022;28(4):773–789. doi:10.3350/cmh.2021.0383
   PubMed Web of Science ®Google Scholar
• Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update. Nutrients. 2020;12(11):3302. doi:10.3390/nu12113302
   PubMed Web of Science ®Google Scholar
• Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the middle east and north Africa. Lancet Gastroenterol Hepatol. 2021;6(1):57–64. doi:10.1016/S2468-1253(20)30213-2
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Gawrieh S. A perspective on RNA interference-based therapeutics for metabolic liver diseases. Expert Opin Investig Drugs. 2021;30(3):237–244. doi:10.1080/13543784.2021.1879792
   PubMed Web of Science ®Google Scholar
• Neuman MG, Seitz HK, French SW, et al. Alcoholic-hepatitis, links to brain and microbiome: mechanisms, clinical and experimental research. Biomedicines. 2020;8(3):63. doi:10.3390/biomedicines8030063
   PubMed Web of Science ®Google Scholar
• Dukić M, Radonjić T, Jovanović I, et al. Alcohol, inflammation, and microbiota in alcoholic liver disease. Int J Mol Sci. 2023;24(4):3735. doi:10.3390/ijms24043735
   PubMed Web of Science ®Google Scholar
• Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16. doi:10.1038/s41572-018-0014-7
   PubMed Web of Science ®Google Scholar
• Seitz HK, Mueller S. Alcoholic Liver Disease. Clin Hepatol. 2010;2:1111–1151.
   Google Scholar
• Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7(8):599–612. doi:10.1038/nrc2191
   PubMed Web of Science ®Google Scholar
• Lieber CS, Rubin E, DeCarli LM. Hepatic microsomal ethanol oxidizing system (MEOS): differentiation from alcohol dehydrogenase and NADPH oxidase. Biochem Biophys Res Commun. 1970;40(4):858–865. doi:10.1016/0006-291X(70)90982-4
   PubMed Web of Science ®Google Scholar
• Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148(1):30–36. doi:10.1053/j.gastro.2014.10.042
   PubMed Web of Science ®Google Scholar
• Theruvathu JA. Polyamines stimulate the formation of mutagenic 1, N2-propanodeoxyguanosine adducts from acetaldehyde. Nucleic Acids Res. 2005;33(11):3513–3520. doi:10.1093/nar/gki661
   PubMed Web of Science ®Google Scholar
• Mizumoto A, Ohashi S, Hirohashi K, Amanuma Y, Matsuda T, Muto M. Molecular mechanisms of acetaldehyde-mediated carcinogenesis in squamous epithelium. Int J Mol Sci. 2017;18(9):1943. doi:10.3390/ijms18091943
   PubMed Web of Science ®Google Scholar
• Song B-J, Abdelmegeed MA, Cho Y-E, et al. Contributing roles of CYP2E1 and other cytochrome p450 isoforms in alcohol-related tissue injury and carcinogenesis. Adv Exp Med Biol. 2019;1164:73–87.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang GJ, Wang Z, et al. High CYP2E1 activity correlates with hepatofibrogenesis induced by nitrosamines. Oncotarget. 2017;8(68):112199–112210. doi:10.18632/oncotarget.22937
   PubMedGoogle Scholar
• Diesinger T, Buko V, Lautwein A, et al. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. PLoS One. 2020;15(7):e0235990. doi:10.1371/journal.pone.0235990
   PubMed Web of Science ®Google Scholar
• Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 2013;58(2):395–398. doi:10.1016/j.jhep.2012.08.018
   PubMed Web of Science ®Google Scholar
• Mallat A, Lotersztajn S. Glutamate signaling in alcohol-associated fatty liver: ”pas de deux”. Hepatology. 2020;72(1):350–352. doi:10.1002/hep.31194
   PubMed Web of Science ®Google Scholar
• Tuma DJ, Thiele GM, Xu D, Klassen LW, Sorrell MF. Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration. Hepatology. 1996;23(4):872–880. doi:10.1002/hep.510230431
   PubMed Web of Science ®Google Scholar
• Chandrasekaran K, Swaminathan K, Mathan Kumar S, Clemens DL, Dey A. In vitro evidence for chronic alcohol and high glucose mediated increased oxidative stress and hepatotoxicity. Alcohol Clin Exp Res. 2012;36(6):1004–1012. doi:10.1111/j.1530-0277.2011.01697.x
   PubMed Web of Science ®Google Scholar
• Zhu L, Yang X, Feng J, et al. CYP2E1 plays a suppressive role in hepatocellular carcinoma by regulating Wnt/Dvl2/β-catenin signaling. J Transl Med. 2022;20(1):194. doi:10.1186/s12967-022-03396-6
   PubMed Web of Science ®Google Scholar
• Mercer KE, Hennings L, Sharma N, et al. Alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis in male mice through activation of the Wnt/beta-catenin signaling pathway. Cancer Prev Res. 2014;7(7):675–685. doi:10.1158/1940-6207.CAPR-13-0444-T
   PubMed Web of Science ®Google Scholar
• Groll N, Petrikat T, Vetter S, et al. Coordinate regulation of Cyp2e1 by beta-catenin- and hepatocyte nuclear factor 1alpha-dependent signaling. Toxicology. 2016;350–352:40–48. doi:10.1016/j.tox.2016.05.004
   PubMed Web of Science ®Google Scholar
• Pandya UM, Egbuta C, Abdullah norman TM, et al. The biophysical interaction of the danger-associated molecular pattern (DAMP) calreticulin with the pattern-associated molecular pattern (pamp) lipopolysaccharide. Int J Mol Sci. 2019;20(2):408. doi:10.3390/ijms20020408
   PubMed Web of Science ®Google Scholar
• Gauthier AE, Rotjan RD, Kagan JC. Lipopolysaccharide detection by the innate immune system may be an uncommon defence strategy used in nature. Open Biology. 2022;12(10). doi:10.1098/rsob.220146
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology. 2006;130(6):1886–1900. doi:10.1053/j.gastro.2006.01.038
   PubMed Web of Science ®Google Scholar
• Wang S, Pacher P, De Lisle RC, Huang H, Ding WX. A mechanistic review of cell death in alcohol-induced liver injury. Alcohol Clin Exp Res. 2016;40(6):1215–1223. doi:10.1111/acer.13078
   PubMed Web of Science ®Google Scholar
• Pone EJ. Analysis by flow cytometry of b-cell activation and antibody responses induced by toll-like receptors. Methods Mol Biol. 2016;1390:229–248.
   PubMedGoogle Scholar
• Amir M, Czaja MJ. Inflammasome-mediated inflammation and fibrosis: it is more than just the IL-1beta. Hepatology. 2018;67(2):479–481. doi:10.1002/hep.29491
   PubMed Web of Science ®Google Scholar
• Uthaya Kumar DB, Chen CL, Liu JC, et al. TLR4 signaling via nanog cooperates with STAT3 to activate twist1 and promote formation of tumor-initiating stem-like cells in livers of mice. Gastroenterology. 2016;150(3):707–719. doi:10.1053/j.gastro.2015.11.002
   PubMed Web of Science ®Google Scholar
• Yeh DW, Liu C, Hernandez JC, Tahara SM, Tsukamoto H, Machida K. Polycomb repressive complex 2 binds and stabilizes NANOG to suppress differentiation-related genes to promote self-renewal. iScience. 2023;26(7):107035. doi:10.1016/j.isci.2023.107035
   PubMed Web of Science ®Google Scholar
• Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA. 2009;106(5):1548–1553. doi:10.1073/pnas.0807390106
   PubMed Web of Science ®Google Scholar
• Lunova M, Trautwein C, Strnad P, Nahon P. Reply to: “Hepatic hepcidin expression is decreased in cirrhosis and HCC. J Hepatol. 2015;62(4):979–980. doi:10.1016/j.jhep.2014.11.008
   PubMed Web of Science ®Google Scholar
• Kohgo Y, Ohtake T, Ikuta K, Suzuki Y, Torimoto Y, Kato J. Dysregulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol. 2008;23:(Suppl 1):S78–81.
   PubMedGoogle Scholar
• Nahon P, Nuraldeen R, Rufat P, Sutton A, Trautwein C, Strnad P. In alcoholic cirrhosis, low-serum hepcidin levels associate with poor long-term survival. Liver Int. 2016;36(2):185–188. doi:10.1111/liv.13007
   PubMed Web of Science ®Google Scholar
• Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res. 2007;31(1 Suppl):S2–8. doi:10.1111/j.1530-0277.2006.00279.x
   PubMedGoogle Scholar
• Nahon P, Sutton A, Rufat P, et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology. 2008;134(1):102–110. doi:10.1053/j.gastro.2007.10.038
   PubMed Web of Science ®Google Scholar
• Yan G, Wang X, Sun C, et al. Chronic alcohol consumption promotes diethylnitrosamine-induced hepatocarcinogenesis via immune disturbances. Sci Rep. 2017;7(1):2567. doi:10.1038/s41598-017-02887-7
   PubMedGoogle Scholar
• Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1alpha activation. Sci Rep. 2016;6(1):21340. doi:10.1038/srep21340
   PubMedGoogle Scholar
• Niture S, Gadi S, Qi Q, et al. MicroRNA-483-5p inhibits hepatocellular carcinoma cell proliferation, cell steatosis, and fibrosis by targeting PPARα and TIMP2. Cancers. 2023;15(6):1715. doi:10.3390/cancers15061715
   PubMed Web of Science ®Google Scholar
• Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. doi:10.1016/j.jhep.2023.06.003
   PubMed Web of Science ®Google Scholar
• Jeong S, Shin WY, Oh YH. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Front Endocrinol. 2023;14:1150360. doi:10.3389/fendo.2023.1150360
   PubMed Web of Science ®Google Scholar
• Mahmoudi A, Jamialahmadi T, Johnston TP, Sahebkar A. Impact of fenofibrate on NAFLD/NASH: a genetic perspective. Drug Discovery Today. 2022;27(8):2363–2372. doi:10.1016/j.drudis.2022.05.007
   PubMed Web of Science ®Google Scholar
• Vachher M, Bansal S, Kumar B, Yadav S, Burman A. Deciphering the role of aberrant DNA methylation in NAFLD and NASH. Heliyon. 2022;8(10):e11119. doi:10.1016/j.heliyon.2022.e11119
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654 e641–649; quiz e639–640. doi:10.1016/j.cgh.2014.04.014
   Web of Science ®Google Scholar
• Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Internat. 2019;13(6):688–694. doi:10.1007/s12072-019-09995-8
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. doi:10.1097/HEP.0000000000000004
   PubMed Web of Science ®Google Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476–1484. doi:10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Tovoli F, Ferri S, Piscaglia F. Hepatocellular carcinoma in non alcoholic fatty liver disease. Curr Pharm Des. 2020;26(32):3909–3914. doi:10.2174/1381612826666200429093648
   PubMed Web of Science ®Google Scholar
• Fujii H, Kawada N; Japan Study Group Of Nafld J-N. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21(11):3863. doi:10.3390/ijms21113863
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu R, Dong J, Li Z. Pathogenesis of NAFLD-related hepatocellular carcinoma: an up-to-date review. J Hepatocell Carcinoma. 2023;10:347–356. doi:10.2147/JHC.S400231
   Web of Science ®Google Scholar
• Kim H, Lee DS, An TH, et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity: from NAFLD to NASH to HCC. Int J Mol Sci. 2021;22(9):1.
   Web of Science ®Google Scholar
• Unluhizarci K, Karaca Z, Kelestimur F. Role of insulin and insulin resistance in androgen excess disorders. World J Diabetes. 2021;12(5):616–629. doi:10.4239/wjd.v12.i5.616
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Insulin resistance: definition and consequences. German Soc End. 2001;109(Suppl 2):S135–148. doi:10.1055/s-2001-18576
   Google Scholar
• Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35(2):238–247. doi:10.1111/j.1365-2036.2011.04929.x
   PubMed Web of Science ®Google Scholar
• Ramai D, Facciorusso A, Vigandt E, et al. Progressive liver fibrosis in non-alcoholic fatty liver disease. Cells. 2021;10(12):3401. doi:10.3390/cells10123401
   PubMed Web of Science ®Google Scholar
• Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semi Cancer Biol. 2013;23(6 Pt B):483–491. doi:10.1016/j.semcancer.2013.07.003
   PubMed Web of Science ®Google Scholar
• Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin Med J. 2022;135(5):547–556. doi:10.1097/CM9.0000000000002089
   PubMed Web of Science ®Google Scholar
• Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13(4):631–647. doi:10.1016/j.cld.2009.07.007
   PubMed Web of Science ®Google Scholar
• Kubota T, Kubota N, Kadowaki T. Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway. Cell Metab. 2017;25(4):797–810. doi:10.1016/j.cmet.2017.03.004
   PubMed Web of Science ®Google Scholar
• Arturi F, Succurro E, Procopio C, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab. 2011;96(10):E1640–E1644. doi:10.1210/jc.2011-1227
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Haque A, Vishwamitra D, et al. Blockade of growth hormone receptor signaling by using pegvisomant: a functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022;12:1.
   Web of Science ®Google Scholar
• Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Current Opinion in Lipidology. 2021;32(3):200–206. doi:10.1097/MOL.0000000000000756
   PubMed Web of Science ®Google Scholar
• Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: clinical challenges of an intriguing link. World J Gastroenterol. 2022;28(3):310–331. doi:10.3748/wjg.v28.i3.310
   PubMed Web of Science ®Google Scholar
• Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208. doi:10.1016/j.cell.2009.12.052
   PubMed Web of Science ®Google Scholar
• Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers. 2019;11(11):1704. doi:10.3390/cancers11111704
   PubMed Web of Science ®Google Scholar
• Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans. Biochim Biophys Acta Rev Cancer. 2019;1871(1):117–125. doi:10.1016/j.bbcan.2018.11.005
   PubMed Web of Science ®Google Scholar
• He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159–168. doi:10.1038/cr.2010.183
   PubMed Web of Science ®Google Scholar
• Wkk W, Zhang L, Chan MTV. Autophagy, NAFLD and NAFLD-Related HCC. Adv Exp Med Biol. 2018;1061:127–138.
   PubMed Web of Science ®Google Scholar
• Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Med. 2002;8(7):731–737. doi:10.1038/nm724
   PubMed Web of Science ®Google Scholar
• Handa P, Maliken BD, Nelson JE, et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology. 2014;60(1):133–145. doi:10.1002/hep.26946
   PubMed Web of Science ®Google Scholar
• Jiang N, Sun R, Sun Q. Leptin signaling molecular actions and drug target in hepatocellular carcinoma. Drug Des Devel Ther. 2014;8:2295–2302. doi:10.2147/DDDT.S69004
   PubMed Web of Science ®Google Scholar
• Wang H, Wang Y, Lai S, et al. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. Cell Death Discov. 2022;8(1):449. doi:10.1038/s41420-022-01234-8
   PubMed Web of Science ®Google Scholar
• Xu FL, You HB, Li XH, Chen XF, Liu ZJ, Gong JP. Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells. Am J Surg. 2008;196(1):139–148. doi:10.1016/j.amjsurg.2007.09.045
   PubMed Web of Science ®Google Scholar
• Ma C, Kesarwala AH, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature. 2016;531(7593):253–257. doi:10.1038/nature16969
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Dungubat E, Kusano H, Fukusato T. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors. Biomedicines. 2023;11(10):2761. doi:10.3390/biomedicines11102761
   PubMed Web of Science ®Google Scholar
• Lai C-Y, Yeh K-Y, Lin C-Y, et al. MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling. Cancers. 2021;13(5):1.
   Web of Science ®Google Scholar
• Tsai W-C, Hsu S-D, Hsu C-S, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Investig. 2012;122(8):2884–2897. doi:10.1172/JCI63455
   PubMed Web of Science ®Google Scholar
• Y-e Q, Duan L, He Y, et al. Saturated fatty acids promote hepatocytic senecence through regulation of mir-34a/cyclin-dependent kinase 6. Molecul Nut. 2020;64(23):2000383.
   Web of Science ®Google Scholar
• Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016;51(10):1022–1030. doi:10.1007/s00535-016-1178-0
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhao X, Steer CJ, Yan G, Song G. A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet. Metabolism. 2018;85:183–191. doi:10.1016/j.metabol.2018.03.023
   PubMed Web of Science ®Google Scholar
• Aspichueta P, Zeisel MB. miR‐21p‐5p coordinates biological pathways to promote MASLD progression. Liver Int. 2023;43(11):2343–2345. doi:10.1111/liv.15740
   PubMed Web of Science ®Google Scholar
• He Y, Hwang S, Cai Y, et al. MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology. 2019;70(4):1150–1167. doi:10.1002/hep.30645
   PubMed Web of Science ®Google Scholar
• Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol. 2015;1(2):222–232. doi:10.1016/j.jcmgh.2015.01.001
   PubMedGoogle Scholar
• Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol. 2019;12:1756284819858470. doi:10.1177/1756284819858470
   Web of Science ®Google Scholar
• Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci. 2018;14(3):701–706. doi:10.5114/aoms.2016.58831
   PubMed Web of Science ®Google Scholar
• Vespasiani-Gentilucci U, Carotti S, Perrone G, et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int. 2015;35(2):569–581. doi:10.1111/liv.12531
   PubMed Web of Science ®Google Scholar
• Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology. 2008;47(5):1773–1785. doi:10.1002/hep.22146
   PubMed Web of Science ®Google Scholar
• Feng L, Chen Y, Xu K, et al. Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD. Aging. 2022;14(7):3259–3275. doi:10.18632/aging.204011
   PubMedGoogle Scholar
• Tanaka S, Hikita H, Tatsumi T, et al. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology. 2016;64(6):1994–2014. doi:10.1002/hep.28820
   PubMed Web of Science ®Google Scholar
• Jang HJ, Lee YH, Dao T, et al. Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy. Exp Mol Med. 2023;55(8):1720–1733. doi:10.1038/s12276-023-01047-4
   PubMed Web of Science ®Google Scholar
• Zhu J, Cheng M, Zhao X. A tRNA-derived fragment (tRF-3001b) aggravates the development of nonalcoholic fatty liver disease by inhibiting autophagy. Life Sci. 2020;257:118125. doi:10.1016/j.lfs.2020.118125
   PubMed Web of Science ®Google Scholar
• Takamura A, Komatsu M, Hara T, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25(8):795–800. doi:10.1101/gad.2016211
   PubMed Web of Science ®Google Scholar
• Inokuchi-Shimizu S, Park EJ, Roh YS, et al. TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. J Clin Invest. 2014;124(8):3566–3578. doi:10.1172/JCI74068
   PubMed Web of Science ®Google Scholar
• Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response. Hepat Med. 2016;8:9–20. doi:10.2147/HMER.S63700
   PubMed Web of Science ®Google Scholar
• He Y, Su Y, Duan C, et al. Emerging role of aging in the progression of NAFLD to HCC. Ageing Res Rev. 2023;84:101833. doi:10.1016/j.arr.2022.101833
   PubMed Web of Science ®Google Scholar
• Baboota RK, Rawshani A, Bonnet L, et al. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH. Nat Metab. 2022;4(8):1007–1021. doi:10.1038/s42255-022-00620-x
   PubMedGoogle Scholar
• Rey S, Quintavalle C, Burmeister K, et al. Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastroenterol Hepatol. 2017;32(8):1480–1486. doi:10.1111/jgh.13717
   PubMed Web of Science ®Google Scholar
• Meijnikman AS, Herrema H, Scheithauer TPM, Kroon J, Nieuwdorp M, Groen AK. Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. JHEP Rep. 2021;3(4):100301. doi:10.1016/j.jhepr.2021.100301
   PubMedGoogle Scholar
• Di Micco R, Krizhanovsky V, Baker D, d’Adda Di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021;22(2):75–95. doi:10.1038/s41580-020-00314-w
   PubMed Web of Science ®Google Scholar
• Li Y, Lu L, Xie Y, et al. Interleukin-6 knockout inhibits senescence of bone mesenchymal stem cells in high-fat diet-induced bone loss. Front Endocrinol. 2020;11:622950. doi:10.3389/fendo.2020.622950
   PubMed Web of Science ®Google Scholar
• Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403–1415. doi:10.1016/j.jhep.2016.02.004
   PubMed Web of Science ®Google Scholar
• Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, Sanyal AJ. A regulatory role of apoptosis antagonizing transcription factor in the pathogenesis of nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatology. 2019;69(4):1520–1534. doi:10.1002/hep.30346
   PubMed Web of Science ®Google Scholar
• Mailliard ME, Gollan JL. Metabolic liver disease in the young adult. Best Pract Res Clin Gastro. 2003;17(2):307–322. doi:10.1016/S1521-6918(02)00148-8
   PubMed Web of Science ®Google Scholar
• Nowak A, Giger RS, Krayenbuehl P-A. Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: a prospective longitudinal observational study. Medicine. 2018;97(42). doi:10.1097/MD.0000000000012886
   Web of Science ®Google Scholar
• Britton RS, Fleming RE, Parkkila S, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis: genetics and beyond. Sem gastro dis. 2002;13(2):68–79.
   PubMedGoogle Scholar
• Adams PC, Jeffrey G, Ryan J. Haemochromatosis. Lancet. 2023;401(10390):1811–1821. doi:10.1016/S0140-6736(23)00287-8
   PubMed Web of Science ®Google Scholar
• Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exper Clinical Cancer Res. 2010;29(1):18. doi:10.1186/1756-9966-29-18
   PubMedGoogle Scholar
• Funakoshi N, Chaze I, Alary AS, et al. The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients. Liver Int. 2016;36(5):746–754. doi:10.1111/liv.12984
   PubMed Web of Science ®Google Scholar
• Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166–2176. doi:10.1038/sj.onc.1210279
   PubMed Web of Science ®Google Scholar
• Lehmann U, Wingen LU, Brakensiek K, et al. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet. 2007;16(11):1335–1342. doi:10.1093/hmg/ddm082
   PubMed Web of Science ®Google Scholar
• Brakensiek K, Länger F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br. J. Haematol. 2005;130(2):209–217. doi:10.1111/j.1365-2141.2005.05590.x
   PubMed Web of Science ®Google Scholar
• Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65(9):3497–3508. doi:10.1158/0008-5472.CAN-04-4088
   PubMed Web of Science ®Google Scholar
• Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione-S-transferase family of enzymes. Mutat Res. 2001;482(1–2):21–26. doi:10.1016/S0027-5107(01)00206-8
   PubMed Web of Science ®Google Scholar
• Di Capua DM, Shanahan W, Bourke M, et al. Tumour stemness and poor clinical outcomes in haemochromatosis patients with hepatocellular carcinoma. J Clin Pathol. 2023;jcp–2022–208679.doi:10.1136/jcp-2022-208679
   Web of Science ®Google Scholar
• Greene CM, Marciniak SJ, Teckman J, et al. α1-Antitrypsin deficiency. Nat Rev Dis Primers. 2016;2(1):16051. doi:10.1038/nrdp.2016.51
   PubMed Web of Science ®Google Scholar
• Crowther DC, Belorgey D, Miranda E, Kinghorn KJ, Sharp LK, Lomas DA. Practical genetics: alpha-1-antitrypsin deficiency and the serpinopathies. Eur J Hum Genet. 2004;12(3):167–172. doi:10.1038/sj.ejhg.5201127
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J Gastrointest Cancer. 2011;42(4):191–194. doi:10.1007/s12029-010-9195-3
   PubMedGoogle Scholar
• Schilsky ML, Oikonomou I. Inherited metabolic liver disease. Curr Opin Gastroenterol. 2005;21(3):275–282. doi:10.1097/01.mog.0000159821.78532.21
   PubMed Web of Science ®Google Scholar
• Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmutter D. Mitochondrial autophagy and injury in the liver in α 1-antitrypsin deficiency. Am J Physiol Gastrointest Liver Physiol. 2004;286(5):G851–G862. doi:10.1152/ajpgi.00175.2003
   PubMed Web of Science ®Google Scholar
• Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 2005;121(7):977–990. doi:10.1016/j.cell.2005.04.014
   PubMed Web of Science ®Google Scholar
• Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology. 2007;45(5):1313–1323. doi:10.1002/hep.21628
   PubMed Web of Science ®Google Scholar
• Rudnick DA, Liao Y, An JK, Muglia LJ, Perlmutter DH, Teckman JH. Analyses of hepatocellular proliferation in a mouse model of alpha-1-antitrypsin deficiency. Hepatology. 2004;39(4):1048–1055. doi:10.1002/hep.20118
   PubMed Web of Science ®Google Scholar
• Angileri F, Morrow G, Scoazec JY, et al. Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1. Sci Rep. 2016;6:27464. doi:10.1038/srep27464
   PubMed Web of Science ®Google Scholar
• Orejuela D, Jorquera R, Bergeron A, Finegold MJ, Tanguay RM. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J Hepatol. 2008;48(2):308–317. doi:10.1016/j.jhep.2007.09.014
   PubMed Web of Science ®Google Scholar
• Willenbring H, Sharma AD, Vogel A, et al. Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008;14(1):59–67. doi:10.1016/j.ccr.2008.05.004
   PubMed Web of Science ®Google Scholar
• Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology. 2007;45(4):968–976. doi:10.1002/hep.21552
   PubMed Web of Science ®Google Scholar
• Angileri F, Morrow G, Roy V, Orejuela D, Tanguay RM. Heat shock response associated with hepatocarcinogenesis in a murine model of hereditary tyrosinemia type I. Cancers. 2014;6(2):998–1019. doi:10.3390/cancers6020998
   PubMed Web of Science ®Google Scholar
• Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. doi:10.1038/s41575-020-00381-6
   PubMed Web of Science ®Google Scholar